Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF

Circulation. 2021 Jul 13;144(2):180-182. doi: 10.1161/CIRCULATIONAHA.121.054034. Epub 2021 Jul 12.

Affiliations

¹ Duke Clinical Research Institute and Duke University School of Medicine, Durham, NC (G.M.F.).
² University of Mississippi Medical Center, Jackson (J.B.).
³ Massachusetts General Hospital, Boston (N.E.I., J.L.J., D.B., A.C.).
⁴ Wayne State University, Detroit, MI (I.L.P.).
⁵ University of California-San Diego (A.M.).
⁶ Novartis Pharmaceuticals, East Hanover, NJ (J.H.W., K.M.W.).
⁷ Brigham and Women's Hospital, Boston, MA (S.D.S.).

No abstract available

Keywords: defibrillators, implantable; heart failure; sacubitril-valsartan; stroke volume.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminobutyrates / pharmacology
Aminobutyrates / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / pharmacology
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Biphenyl Compounds / pharmacology
Biphenyl Compounds / therapeutic use*
Chronic Disease
Defibrillators, Implantable / standards*
Female
Heart Failure / drug therapy*
Heart Failure / therapy*
Humans
Male
Valsartan / pharmacology
Valsartan / therapeutic use*

Substances

Aminobutyrates
Angiotensin II Type 1 Receptor Blockers
Biphenyl Compounds
sacubitril
Valsartan